News & Resources All Press Releases Presentations & Publications Press Releases GSK completes acquisition of IDRx, Inc. February 24, 2025 Press Releases GSK enters agreement to acquire IDRx, Inc. January 13, 2025 Presentations & Publications The Novel Kit Inhibitor IDRX-42 Shows Promising Activity In 2nd And Later-line Gastrointestinal Stromal Tumors: Results From A Phase 1 Study (StrateGIST 1) November 14, 2024 Press Releases IDRx Announces Updated Phase 1 Data from Ongoing Phase 1/1b StrateGIST 1 Trial of IDRX-42 in Advanced Gastrointestinal Stromal Tumors (GIST) at CTOS 2024 November 14, 2024 Press Releases IDRx Announces $120 Million Series B Financing to Advance Potential Best-in-class New Treatment for Gastrointestinal Stromal Tumor (GIST) August 7, 2024 Presentations & Publications StrateGIST 1: a first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs) June 3, 2024 Press Releases IDRx Reports Updated Preliminary Phase 1 Data from Ongoing Phase 1/1b StrateGIST 1 Trial Supporting Best-in-Class Potential for IDRX-42 in Patients with GIST June 3, 2024 Press Releases IDRx Appoints David P. Kerstein, M.D., as Chief Medical Officer March 27, 2024 Press Releases IDRx Strengthens Executive Team with Appointments of Tim Clackson, Ph.D., as CEO and Brad Dahms as CFO and CBO March 12, 2024 Load More Press Releases GSK completes acquisition of IDRx, Inc. February 24, 2025 Press Releases GSK enters agreement to acquire IDRx, Inc. January 13, 2025 Press Releases IDRx Announces Updated Phase 1 Data from Ongoing Phase 1/1b StrateGIST 1 Trial of IDRX-42 in Advanced Gastrointestinal Stromal Tumors (GIST) at CTOS 2024 November 14, 2024 Press Releases IDRx Announces $120 Million Series B Financing to Advance Potential Best-in-class New Treatment for Gastrointestinal Stromal Tumor (GIST) August 7, 2024 Press Releases IDRx Reports Updated Preliminary Phase 1 Data from Ongoing Phase 1/1b StrateGIST 1 Trial Supporting Best-in-Class Potential for IDRX-42 in Patients with GIST June 3, 2024 Press Releases IDRx Appoints David P. Kerstein, M.D., as Chief Medical Officer March 27, 2024 Press Releases IDRx Strengthens Executive Team with Appointments of Tim Clackson, Ph.D., as CEO and Brad Dahms as CFO and CBO March 12, 2024 Press Releases IDRx Presents Preliminary Clinical Data from Ongoing Phase 1 StrateGIST Study at CTOS 2023 Supporting Best-in-Class Potential of IDRX-42 in Patients with GIST November 2, 2023 Press Releases IDRx Launches with $122 Million Series A Financing to Treat Cancer with Purpose-Built Precision Combination Therapies August 2, 2022 Presentations & Publications The Novel Kit Inhibitor IDRX-42 Shows Promising Activity In 2nd And Later-line Gastrointestinal Stromal Tumors: Results From A Phase 1 Study (StrateGIST 1) November 14, 2024 Presentations & Publications StrateGIST 1: a first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs) June 3, 2024 Presentations & Publications Phase 1 Study of IDRX-42 in Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Prior Systemic Therapy: Early Results November 2, 2023 Presentations & Publications Anti-tumor efficacy of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell line-derived xenograft models of gastrointestinal stromal tumor (GIST) May 24, 2023 Presentations & Publications Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors February 2, 2023 Presentations & Publications Anti-tumor Effects of the Novel KIT Inhibitor IDRX-42 (formerly M4205) in Gastrointestinal Stromal Tumor (GIST) Xenograft Models November 18, 2022 Presentations & Publications Anti-tumor effects of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell lined-derived xenograft models of gastrointestinal stromal tumor (GIST) September 28, 2022
